Cameron Santoro

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for risk-based screening strategies that account for factors like breast density, hormone replacement therapy, and family cancer history to improve early detection.

Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.

Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological diseases through teledermatology.

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, highlights the continued relevance of older, generic dermatologic therapies despite the availability of newer, targeted treatments.

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.

Experts discussed advancements in dermatology treatment while emphasizing the value of in-person collaboration and professional rejuvenation at the American Academy of Dermatology 2025 conference.

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric alopecia areata and highlights the need for personalized treatment approaches based on Janus kinase inhibitor responses.

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic dermatitis, its potential to reduce the need for systemic therapies, and the significant role of the skin microbiome in disease management.

Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.

Steven Daniel Daveluy, MD, FAAD, advocates for dermatologists to adopt cultural humility, engage in continuous education, and navigate ethical considerations to provide equitable and supportive care to LGBTQ patients.

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ruxolitinib for itch and inflammation, while also outlining a comprehensive approach to chronic pruritus management.

Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, advocates for teledermatology as a vital tool to enhance health care equity by improving access for underserved populations and reducing physician burnout.

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing the balance between treatment efficacy and safety.

Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing personalized care based on patient history and the favorable long-term safety profile of topical ruxolitinib.

Rebecca Vasquez, MD, FAAD, University of Texas Southwestern Medical Center, emphasizes the necessity of addressing social determinants to improve dermatological care and access for underserved populations.

Strict changes to immigration policies nationwide create a public health crisis in overcrowded detention centers, draining taxpayer dollars and diminishing undocumented immigrants' contributions to subsidies.

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations.

Seemal R Desai, MD, FAAD, president of the American Academy of Dermatology (AAD), emphasized his commitment to enhancing the upcoming 2025 annual meeting by introducing new events and expanding educational offerings to better serve and engage members.

Time costs, often overlooked in health care, create economic burdens for patients and caregivers, impacting income and well-being.

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising rates of type 2 diabetes and obesity.

Jeffrey Stark, MD, vice president, head of medical immunology, UCB, discusses ongoing clinical trials and the development of real-world data to understand the effectiveness of bimekizumab-bkzx in a broader context.

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, analyzes the Bimzelx Navigate program, a comprehensive support system developed to empower patients prescribed bimekizumab-bkzx (Bimzelx; UCB).

Merilog (insulin-aspart-szjj) is the first rapid-acting insulin biosimilar to Novolog (insulin aspart) that is designated to improve glycemic control in adults and adolescents with type 2 diabetes.

The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to improve care, reduce costs, and address health equity for patients with skin diseases.

The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss, and other endocrine diseases.

To maintain a healthy heart, researchers say people should focus on diet and exercise, limit alcohol, manage stress, get enough sleep, and more.

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable treatment option for patients.

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into practice due to high costs and a lack of targeted initiatives to aid health care providers with integration.